Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 19/20 | 0.81 |
| ▸ | FXR2 | P51116 | 1/20 | 0.55 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20048976 | 0.97 | NR1H4 (0.77) | NR1H4FXR2HSD17B13 | |
| SCHEMBL21703964 | 0.92 | NR1H4 (0.74) | NR1H4FXR2HSD17B13 | |
| SCHEMBL20043485 | 0.92 | NR1H4 (0.69) | NR1H4FXR2 | |
| SCHEMBL20049503 | 0.91 | NR1H4 (0.70) | NR1H4FXR2HSD17B13 | |
| SCHEMBL19739533 | 0.90 | NR1H4 (1.00) | NR1H4FXR2 | |
| SCHEMBL17128508 | 0.90 | NR1H4 (1.00) | NR1H4FXR2 | |
| SCHEMBL17861443 | 0.90 | NR1H4 (1.00) | NR1H4FXR2 | |
| SCHEMBL17128505 | 0.90 | NR1H4 (1.00) | NR1H4FXR2 | |
| SCHEMBL9958227 | 0.90 | NR1H4 (1.00) | NR1H4FXR2 | |
| SCHEMBL20043507 | 0.90 | NR1H4 (0.67) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | NR1H4 3/4885FXR2 6/4885HSD17B13 310/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | NR1H4 3/4885FXR2 6/4885HSD17B13 310/4885 |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | NR1H4 3/4885FXR2 6/4885HSD17B13 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.